Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34).

Suzuki Y, Nagase Y, Iga K, Kawase M, Oka M, Yanai S, Matsumoto Y, Nakagawa S, Fukuda T, Adachi H, Higo N, Ogawa Y

Journal of pharmaceutical sciences1 Feb 2002Cited by 30 (Europe PMC)

PMID11835195DOI10.1002/jps.10019PepBankPUB-11835195

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH at 1 microg/kg/day produced relative femoral bone density of 104% of vehicle.
In plain wordsIn rats, PTH at 1 microg/kg/day increased femoral bone density compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur bone mineral density
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Vehicle injection
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/day · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
Relative BMD
104%
1 microg/kg/day versus vehicle
Source sentences
Summary
For the sc administration, the relative BMD values using the vehicle injection as a reference standard for 1, 5, and 25 microg/kg/day were 104, 114, and 121%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
Report a problemFND-1183519502
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH at 5 microg/kg/day produced relative femoral bone density of 114% of vehicle.
In plain wordsIn rats, PTH at 5 microg/kg/day increased femoral bone density compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur bone mineral density
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Vehicle injection
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/day · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
Relative BMD
114%
5 microg/kg/day versus vehicle
Source sentences
Summary
For the sc administration, the relative BMD values using the vehicle injection as a reference standard for 1, 5, and 25 microg/kg/day were 104, 114, and 121%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
Report a problemFND-1183519503
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH at 25 microg/kg/day produced relative femoral bone density of 121% of vehicle.
In plain wordsIn rats, PTH at 25 microg/kg/day increased femoral bone density compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur bone mineral density
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Vehicle injection
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 microg/kg/day · subcutaneous · 4 weeksAs given in this study (rat).
Measurements
Relative BMD
121%
25 microg/kg/day versus vehicle
Source sentences
Summary
For the sc administration, the relative BMD values using the vehicle injection as a reference standard for 1, 5, and 25 microg/kg/day were 104, 114, and 121%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
Report a problemFND-1183519504
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, iontophoretic PTH at 40 microg/patch produced relative femoral bone density of 104% of placebo.
In plain wordsIn rats, iontophoretic PTH at 40 microg/patch increased femoral bone density compared with placebo patches.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur bone mineral density
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Placebo patch
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/patch · Transdermal iontophoresis · 4 weeksAs given in this study (rat).
Measurements
Relative BMD
104%
40 microg/patch versus placebo
Source sentences
Summary
For iontophoretic administration, the relative BMD values using the placebo patch as a reference standard for 40, 120, and 400 microg/patch were 104, 110, and 116%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
Report a problemFND-1183519505
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, iontophoretic PTH at 120 microg/patch produced relative femoral bone density of 110% of placebo.
In plain wordsIn rats, iontophoretic PTH at 120 microg/patch increased femoral bone density compared with placebo patches.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur bone mineral density
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Placebo patch
Outcome group
Bone and joint · Musculoskeletal
Studied dose
120 microg/patch · Transdermal iontophoresis · 4 weeksAs given in this study (rat).
Measurements
Relative BMD
110%
120 microg/patch versus placebo
Source sentences
Summary
For iontophoretic administration, the relative BMD values using the placebo patch as a reference standard for 40, 120, and 400 microg/patch were 104, 110, and 116%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
Report a problemFND-1183519506
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, iontophoretic PTH at 400 microg/patch produced relative femoral bone density of 116% of placebo.
In plain wordsIn rats, iontophoretic PTH at 400 microg/patch increased femoral bone density compared with placebo patches.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDistal femur bone mineral density
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Comparator
Placebo patch
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 microg/patch · Transdermal iontophoresis · 4 weeksAs given in this study (rat).
Measurements
Relative BMD
116%
400 microg/patch versus placebo
Source sentences
Summary
For iontophoretic administration, the relative BMD values using the placebo patch as a reference standard for 40, 120, and 400 microg/patch were 104, 110, and 116%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
Report a problemFND-1183519507

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Pharmacokinetics
In ovariectomized rats, triple-pulse iontophoresis produced three sharp serum PTH peaks proportional to dose.
In plain wordsIn rats, triple-pulse iontophoresis produced three blood PTH peaks that increased with dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerum PTH peaks
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Triple-pulse iontophoretic administration of hPTH(1-34) (doses: 40-400 microg/patch), achieved by repeated 30-min applications of a 0.1 mA/cm(2) current separated by 45-min rest intervals, produced three sharp peaks in the serum hPTH(1-34) level in response to application of the current.
2 context sentences(design, population, supporting numbers)
Summary · context
Each peak appeared at the end of the 30-min current application period and was proportional to the hPTH(1-34) dose.
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1183519501
08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, bone density versus weekly PTH exposure showed similar relationships for iontophoretic and subcutaneous delivery.
In plain wordsIn rats, bone density had similar relationships with weekly PTH exposure for iontophoretic and injected treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone density versus weekly AUC
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The increase in the BMD plotted against the area under the hPTH(1-34) serum level-time curve (AUC) over 1 week resulted in similar straight lines in the 9 pulses/week iontophoretic administration and the 7 pulses/week sc administration groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1183519508
09AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, 120 microg/patch was estimated to match bone density with subcutaneous PTH at 5 microg/kg/day.
In plain wordsIn rats, iontophoretic PTH at 120 microg/patch was estimated to match bone density with injections at 5 microg/kg/day.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableEquivalent iontophoretic dose
Study
ratn: not reported in source
Ovariectomized Sprague Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The estimated iontophoretic dose giving an equivalent BMD to once-daily sc administration at 5 microg/kg/day was 120 microg/patch.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum human parathyroid hormone (1-34)[hPTH(1-34)] levels and the anabolic effect of hPTH(1-34) were compared after administration using multiple pulses of iontophoresis or subcutaneous (sc) intermittent injections to ovariectomized (OVX) Sprague Dawley rats.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1183519509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.